COO Q3 Deep Dive: Product Momentum and Strategic Review Shape Outlook

Medical device company CooperCompanies (NASDAQ:COO) met Wall Streets revenue expectations in Q3 CY2025, with sales up 4.6% year on year to $1.07 billion. The company expects next quarter’s revenue to be around $1.02 billion, coming in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.15 per share was 3.2% above analysts’ consensus estimates.

Is now the time to buy COO? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

CooperCompanies delivered a third quarter that met market expectations, with management highlighting robust execution in its premium daily contact lens portfolio and steady contract wins in both private label and branded products. CEO Al White attributed the performance to the global rollout of the MyDay lens line, stating, “Momentum is robust, we’re seeing increasing bidding activity with especially strong interest in our premium comfort MyDay Energous lens.” Despite ongoing softness in the Asia Pacific region, particularly China, management pointed to improved availability and targeted product launches as key drivers behind CooperVision’s growth. CooperSurgical’s performance was supported by share gains in fertility and strong demand for the PARAGARD device, offsetting weaker consumer spending in certain markets.

Looking ahead, management’s guidance reflects optimism around further market share gains and product launches in both the vision and surgical segments. White emphasized, “We expect this momentum to continue into next year, with the upcoming launches of MyDay MySight across Europe and MiSight in Japan.” The company also expects free cash flow improvements, driven by cost-saving initiatives and declining capital expenditures as recent investments wind down. Strategic priorities include executing on new private label contracts, ongoing evaluation of portfolio options, and a commitment to shareholder returns through repurchases and operational efficiency. Management cautioned that continued market softness in Asia Pacific and the impact of tariffs could remain headwinds, but expressed confidence that new product introductions and operational streamlining will offset these factors.

Key Insights from Management’s Remarks

Management credited quarterly results to the strong uptake of premium daily lenses, ongoing contract wins, and disciplined cost control, while acknowledging regional headwinds and the early stages of a broader strategic review.

• Premium lens momentum: CooperVision’s MyDay portfolio saw double-digit growth, with particular strength in toric and multifocal variants, supporting steady global share gains. Management noted that the shift toward premium daily lenses is accelerating, especially in developed markets.

• Regional divergence: While the Americas and EMEA (Europe, Middle East, Africa) contributed to growth, Asia Pacific lagged due to a 28% decline in China’s lower-margin e-commerce channels. Management emphasized a strategy of prioritizing profitability and not chasing aggressively priced volume in China.

• Surgical division execution: CooperSurgical’s results were supported by new product launches, including the PARAGARD single-hand inserter and growth in its OBP surgical line. Management expects recent wins in fertility genomics and automated lab tracking systems to drive future momentum.

• Cost efficiency and restructuring: Significant reorganization and integration efforts, particularly in support functions and leveraging AI, yielded meaningful cost savings. CFO Brian Andrews highlighted $50 million in expected annual pretax savings, enabling margin expansion even amidst gross margin pressure from tariffs and product mix.

• Strategic review and governance: The board initiated a formal review of strategic alternatives, including the possibility of separating CooperVision and CooperSurgical, and announced a leadership transition with Colleen Jay becoming chair. Management also added total shareholder return as a metric in executive compensation plans to align incentives.

Drivers of Future Performance

Management expects future results to be driven by continued innovation in premium lenses, execution on new contracts, and disciplined cost management, while monitoring external risks.

• Product launches and contract execution: Upcoming launches of MyDay MySight and MiSight in new markets, along with continued global expansion of private label contracts, are expected to drive revenue growth, especially in the latter half of the year as these products gain traction.

• Operational efficiency and cash flow: Cost-saving measures from reorganization, lower capital expenditures as major investment cycles end, and tighter working capital management are projected to improve operating margins and free cash flow, with a target of over $2.2 billion by 2028.

• External headwinds and market variability: Management highlighted potential risks from ongoing tariff impacts, regional economic softness (notably in Asia Pacific), and competition in both vision and surgical markets. Guidance assumes conservative growth in fertility and PARAGARD, factoring in competitive launches and consumer spending uncertainty.

Catalysts in Upcoming Quarters

In future quarters, our analysts will track (1) the pace of new product launches, particularly the rollout of MyDay MySight in Europe and MiSight in Japan, (2) evidence of margin expansion and cash flow improvement as restructuring benefits materialize, and (3) progress on the board’s strategic review, including any announcements regarding portfolio changes. Developments in the Asia Pacific market and competitive responses in the fertility and surgical segments will also be key indicators of execution.

CooperCompanies currently trades at $82.19, up from $77.30 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

High Quality Stocks for All Market Conditions

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.